Skip to main content

Clifford Chance

Clifford Chance
Dr. Ulrich Reese

Dr. Ulrich Reese


  • en
  • de
  • Language options
Dr. Ulrich Reese
Dr. Ulrich Reese

Ulrich Reese co-heads the global Healthcare and Life Sciences Sector Group at Clifford Chance.

He advises a broad range of international co-operations on the manufacturing, marketing, distribution and reimbursement of medicinal products and devices and is a private lecturer for pharmaceutical law at the University of Marburg. Further, Ulrich Reese is a regular advisor of the leading trade associations on a national and European level.

Ulrich Reese ist Co-Leiter unserer globalen Healthcare & Life Sciences Sector Group. Er berät ein breites Spektrum nationaler und internationaler Unternehmen bei der Herstellung, Vermarktung, dem Vertrieb und der Erstattung von Arzneimitteln und Medizinprodukten und verfügt über weitere Expertise bei Lizenz- und Kooperationsverträgen.

Ulrich Reese berät auch regelmäßig führende Industrieverbände auf nationaler und europäischer Ebene. Darüber hinaus ist er Privatdozent für Pharmarecht an der Universität Marburg.

  • Merck on the conclusion of the global strategic collaboration agreement with GlaxoSmithKline regarding M7824 (Bintrafusp alfa)
  • GlaxoSmithKline on the establishment of mixed prices for new medicines
  • Fresenius on research and collaboration/partnering projects with Sandoz in the field of EPO
  • Fresenius on research and collaboration/partnering projects with
    • Baxter in the field of anticoagulation
    • Bayer in the field of anticoagulation
    • Octapharma in the field of anticoagulation
  • Pfizer on a global in-licensing project in the field of anti-infectives
  • Fresenius Kabi on the acquisition of Merck KGaA’s biosimilars business
  • SCA Group on the acquisition of BSN medical from EQT
  • Cinven and KKR on the proposed acquisition of the Roche Consumer Healthcare business
  • Pfizer with respect to two divestitures of businesses in the course of the integration of Hospira
  • Takeda with regard to the disposal of an OTC product portfolio to Dr. Kade
  • Grünenthal on the sale of its worldwide oral contraceptive portfolio to Gedeon Richter Group
  • Pfizer on the disposal of its European veterinary medicinal product portfolio to Elanco
  • Pfizer on the disposal of Heumann PCS to Fareva
  • Pfizer in connection with transactions and with regard to market access / reimbursement, advertising and product liability
  • Bayer HealthCare on advertising law in the scope of their major product launch Xarelto
  • International pharmaceutical companies in various partnering and licensing projects
  • International pharmaceutical companies in market and launch defence
  • International companies in connection with the defense of parallel imports and re-imports
  • International pharmaceutical companies in the field of market access
  • International companies on social and public procurement disputes.
  • Beratung internationaler Pharmaunternehmen bei verschiedenen Partnering- und Lizenzprojekten
  • Beratung internationaler Pharmaunternehmen bei der Markteinführung und Launch-Abwehr
  • Beratung internationaler Unternehmen im Zusammenhang mit der Abwehr von Parallel- und Reimporten
  • Beratung internationaler Pharmaunternehmen im Bereich Market Access
  • Beratung internationaler Unternehmen in sozial- und vergaberechtlichen Auseinandersetzungen

News and client work

View all news and client work featuring Ulrich Reese

Contact details


Career and qualifications

  • Admitted as a Rechtsanwalt in Germany 1995
  • Joined Clifford Chance as Partner 2007


  • Seit 1995 als Rechtsanwalt in Deutschland zugelassen
  • Bei Clifford Chance als Partner seit 2007

Professional bodies

  • He is a visiting lecturer at the Pharmaceutical Law department of the University of Marburg
  • Legal advisor to and Member of legal committees of the main trade associations in the healthcare sector
  • He is co-chair of the Committee for Pharmaceutical and Nutritional Law of the German Association of Intellectual Property and Copyright (Gesellschaft für gewerblichen Rechtsschutz und Urheberrecht – GRUR)


  • Privatdozent an der Universität Marburg (Zusatzqualifikation Pharmarecht)
  • Rechtsberater und Mitglied der Rechtsausschüsse der wichtigsten Wirtschaftsverbände im Gesundheitswesen
  • Vorsitzender des Fachausschusses „Arzneimittelrecht/Lebensmittelrecht“ der Deutschen Vereinigung für Gewerblichen Rechtsschutz (GRUR)

Awards and citations

  • “Ulrich Reese is technically really outstanding, with long-standing experience.”
    Chambers Europe 2023 - Life Sciences
  • Band 1
    Ulrich Reese is highly respected in the market for his extensive knowledge of life sciences regulations [… ] Clients say he is "creative, constructive, pragmatic and outstanding when it comes to new areas without much case law."
    Chambers Europe 2022: Germany - Life Sciences 
  • Leading Individual
    JUVE 2022 - Pharmaceutical and Medical Device Law 
  • Leading Individual
    "Ulrich Reese has an impressive understanding of medical and biological issues, which forms the basis for advising and then representing in court proceedings. Crystal-clear analysis, concentration on the essentials and impressive experience in drug advertising combined with eloquence in pleadings and in court characterize his work."
    "Always approachable, gets back to you quickly. Good problem solutions are developed on the basis of his technical expertise and his analytical thinking."
    Legal 500 EMEA 2022: Germany - Healthcare and Life Sciences
  • Thought Leader
    Who's Who Legal 2022: Germany - Life Sciences
  • Leading lawyer, "competent, reliable, fast, excellent process management", "very great performance"
    JUVE 2021/22 - Pharmaceuticals and Medical Products
  • Band 1
    Ulrich Reese acts for global pharmaceutical companies, handling co-operation agreements and market access issues. He also represents clients in contentious mandates, covering patents and unfair competition. One client says: "He has immense expertise and is very well organised with timely responses. His style is fact-based, deliberate and strategic."
    Chambers Europe 2020: Germany - Life Sciences
  • Band 1
    JUVE 2020 - Pharmaceutical and Medical Device Law
  • Leading Individual
    "Ulrich Reese is one of the top experts in the field of pharmaceutical law, who combines excellent legal knowledge with deep industry knowledge."
    "Ulrich Reese offers excellent industry knowledge in the regulatory and transactional area. Experienced, persistent and skillful."
    Legal 500 EMEA: Germany - Healthcare and Life Sciences
  • "He has immense expertise and is very well organised with timely responses. His style is fact-based, deliberate and strategic."
    Chambers Europe: Germany 2020 - Healthcare
  • "Ulrich Reese is one of the top experts in the field of pharmaceutical law, combining excellent legal knowledge with deep industry expertise. He delivers excellent legal opinions and pleadings. The argumentation is to the point."
    Legal500 Germany 2020 - Healthcare


    • „Ulrich Reese ist technisch wirklich hervorragend, mit langjähriger Erfahrung.“
      Chambers Europe 2023 - Life Sciences
    • Führender Berater, „kompetent, zuverlässig, schnell, exzellente Prozessführung“, „ganz große Leistung“
      JUVE 2021/22 - Pharma/Medizinprodukte
    • „Er verfügt über immense Fachkenntnisse und ist sehr gut organisiert mit zeitnahen Antworten. Sein Stil ist faktenbasiert, bedacht und strategisch.“
      Chambers Europe: Deutschland 2020 - Gesundheitswesen
    • „Ulrich Reese ist einer der Top-Experten auf dem Gebiet des Pharmarechts, der exzellente Rechtskenntnisse mit tiefen Branchenkenntnissen vereint. Er liefert exzellente Gutachten und Schriftsätze. Die Argumentation ist auf den Punkt.“
      Legal500 Deutschland 2020 - Gesundheit